On September 7, 2023 Mustang Bio, Inc. ("Mustang") (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, reported that Manuel Litchman, M.D., President and Chief Executive Officer, will participate in two upcoming investor conferences in New York City (Press release, Mustang Bio, SEP 7, 2023, View Source [SID1234635001]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the events are as follows:

H.C. Wainwright 25th Annual Global Investment Conference: The company will present a corporate update on Monday, September 11, 2023, at 3:30 p.m. ET and will participate in one-on-one meetings during the conference.

2023 Cantor Fitzgerald Global Healthcare Conference: The company will participate in a panel presentation on Wednesday, September 27, 2023, at 8:35 a.m. ET and will participate in one-on-one meetings during the conference.

A webcast and subsequent archived replay of each of the company’s presentations will be available on the News & Events page of the Investor Relations section of Mustang’s website, www.mustangbio.com, for approximately 30 days after each meeting.